New drug aims to thicken nerves and strengthen grip in rare nerve disorder
NCT ID NCT07610564
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental drug called empasiprubart in 60 adults with multifocal motor neuropathy (MMN), a rare condition that causes muscle weakness. The drug is given as an IV infusion, and researchers will use ultrasound to measure nerve thickness, along with tests of muscle strength and grip. The study is open-label, meaning everyone gets the drug, and participants will be followed for about 29 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
empasiprubart (intravenous infusion)
What this could lead to
If it works, this could point toward a treatment that slows nerve damage and improves muscle strength in people with multifocal motor neuropathy.
What could go wrong
This is a very early, small Phase 1b study with no placebo group, so results may not prove effectiveness. The drug may cause side effects or fail to show meaningful benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIFOCAL MOTOR NEUROPATHY (MMN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••